Effect of increased potassium intake on the renin-angiotensin-aldosterone system and subcutaneous resistance arteries: a randomized crossover study

Publikation: Bidrag til tidsskriftTidsskriftartikelfagfællebedømt

Standard

Effect of increased potassium intake on the renin-angiotensin-aldosterone system and subcutaneous resistance arteries : a randomized crossover study. / Dreier, Rasmus; Abdolalizadeh, Bahareh; Asferg, Camilla L; Hölmich, Lisbet R; Buus, Niels H; Forman, Julie L; Andersen, Ulrik B.; Egfjord, Martin; Sheykhzade, Majid; Jeppesen, Jørgen L.

I: Nephrology, Dialysis, Transplantation, Bind 36, Nr. 7, 2021, s. 1282–1291.

Publikation: Bidrag til tidsskriftTidsskriftartikelfagfællebedømt

Harvard

Dreier, R, Abdolalizadeh, B, Asferg, CL, Hölmich, LR, Buus, NH, Forman, JL, Andersen, UB, Egfjord, M, Sheykhzade, M & Jeppesen, JL 2021, 'Effect of increased potassium intake on the renin-angiotensin-aldosterone system and subcutaneous resistance arteries: a randomized crossover study', Nephrology, Dialysis, Transplantation, bind 36, nr. 7, s. 1282–1291. https://doi.org/10.1093/ndt/gfaa114

APA

Dreier, R., Abdolalizadeh, B., Asferg, C. L., Hölmich, L. R., Buus, N. H., Forman, J. L., Andersen, U. B., Egfjord, M., Sheykhzade, M., & Jeppesen, J. L. (2021). Effect of increased potassium intake on the renin-angiotensin-aldosterone system and subcutaneous resistance arteries: a randomized crossover study. Nephrology, Dialysis, Transplantation, 36(7), 1282–1291. https://doi.org/10.1093/ndt/gfaa114

Vancouver

Dreier R, Abdolalizadeh B, Asferg CL, Hölmich LR, Buus NH, Forman JL o.a. Effect of increased potassium intake on the renin-angiotensin-aldosterone system and subcutaneous resistance arteries: a randomized crossover study. Nephrology, Dialysis, Transplantation. 2021;36(7):1282–1291. https://doi.org/10.1093/ndt/gfaa114

Author

Dreier, Rasmus ; Abdolalizadeh, Bahareh ; Asferg, Camilla L ; Hölmich, Lisbet R ; Buus, Niels H ; Forman, Julie L ; Andersen, Ulrik B. ; Egfjord, Martin ; Sheykhzade, Majid ; Jeppesen, Jørgen L. / Effect of increased potassium intake on the renin-angiotensin-aldosterone system and subcutaneous resistance arteries : a randomized crossover study. I: Nephrology, Dialysis, Transplantation. 2021 ; Bind 36, Nr. 7. s. 1282–1291.

Bibtex

@article{71c91f9e18d94adb992bc6e18745005c,
title = "Effect of increased potassium intake on the renin-angiotensin-aldosterone system and subcutaneous resistance arteries: a randomized crossover study",
abstract = "BACKGROUND: Increased potassium intake lowers blood pressure (BP) in hypertensive patients. The underlying mechanism is not fully understood but must be complex because increased potassium intake elevates circulating concentrations of the BP-raising hormone aldosterone.METHODS: In a randomized placebo-controlled crossover study in 25 normotensive men, we investigated the effect of 4 weeks of potassium supplement (90 mmol/day) compared with 4 weeks of placebo on the renin-angiotensin-aldosterone system (RAAS), urine composition and 24-h ambulatory BP. Vascular function was also assessed through wire myograph experiments on subcutaneous resistance arteries from gluteal fat biopsies.RESULTS: Higher potassium intake increased urinary potassium excretion (144.7 ± 28.7 versus 67.5 ± 25.5 mmol/24-h; P < 0.0001) and plasma concentrations of potassium (4.3 ± 0.2 versus 4.0 ± 0.2 mmol/L; P = 0.0002), renin {mean 16 [95% confidence interval (CI) 12-23] versus 11 [5-16] mIU/L; P = 0.0047}, angiotensin II [mean 10.0 (95% CI 6.2-13.0) versus 6.1 (4.0-10.0) pmol/L; P = 0.0025] and aldosterone [mean 440 (95% CI 336-521) versus 237 (173-386) pmol/L; P < 0.0001]. Despite RAAS activation, systolic BP (117.6 ± 5.8 versus 118.2 ± 5.2 mmHg; P = 0.48) and diastolic BP (70.8 ± 6.2 versus 70.8 ± 6.3 mmHg; P = 0.97) were unchanged. In the wire myograph experiments, higher potassium intake did not affect endothelial function as assessed by acetylcholine [logarithmically transformed half maximal effective concentration (pEC50): 7.66 ± 0.95 versus 7.59 ± 0.85; P = 0.86] and substance P (pEC50: 8.42 ± 0.77 versus 8.41 ± 0.89; P = 0.97) or vascular smooth muscle cell reactivity as assessed by angiotensin II (pEC50: 9.01 ± 0.86 versus 9.02 ± 0.59; P = 0.93) and sodium nitroprusside (pEC50: 7.85 ± 1.07 versus 8.25 ± 1.32; P = 0.25) but attenuated the vasodilatory response of retigabine (pEC50: 7.47 ± 1.16 versus 8.14 ± 0.90; P = 0.0084), an activator of Kv7 channels.CONCLUSIONS: Four weeks of increased potassium intake activates the RAAS in normotensive men without changing BP and this is not explained by improved vasodilatory responses ex vivo.",
author = "Rasmus Dreier and Bahareh Abdolalizadeh and Asferg, {Camilla L} and H{\"o}lmich, {Lisbet R} and Buus, {Niels H} and Forman, {Julie L} and Andersen, {Ulrik B.} and Martin Egfjord and Majid Sheykhzade and Jeppesen, {J{\o}rgen L}",
note = "Correction to: Effect of increased potassium intake on the renin–angiotensin–aldosterone system and subcutaneous resistance arteries: a randomized crossover study. DOI: 10.1093/ndt/gfaa292",
year = "2021",
doi = "10.1093/ndt/gfaa114",
language = "English",
volume = "36",
pages = "1282–1291",
journal = "Nephrology, Dialysis, Transplantation",
issn = "0931-0509",
publisher = "Oxford University Press",
number = "7",

}

RIS

TY - JOUR

T1 - Effect of increased potassium intake on the renin-angiotensin-aldosterone system and subcutaneous resistance arteries

T2 - a randomized crossover study

AU - Dreier, Rasmus

AU - Abdolalizadeh, Bahareh

AU - Asferg, Camilla L

AU - Hölmich, Lisbet R

AU - Buus, Niels H

AU - Forman, Julie L

AU - Andersen, Ulrik B.

AU - Egfjord, Martin

AU - Sheykhzade, Majid

AU - Jeppesen, Jørgen L

N1 - Correction to: Effect of increased potassium intake on the renin–angiotensin–aldosterone system and subcutaneous resistance arteries: a randomized crossover study. DOI: 10.1093/ndt/gfaa292

PY - 2021

Y1 - 2021

N2 - BACKGROUND: Increased potassium intake lowers blood pressure (BP) in hypertensive patients. The underlying mechanism is not fully understood but must be complex because increased potassium intake elevates circulating concentrations of the BP-raising hormone aldosterone.METHODS: In a randomized placebo-controlled crossover study in 25 normotensive men, we investigated the effect of 4 weeks of potassium supplement (90 mmol/day) compared with 4 weeks of placebo on the renin-angiotensin-aldosterone system (RAAS), urine composition and 24-h ambulatory BP. Vascular function was also assessed through wire myograph experiments on subcutaneous resistance arteries from gluteal fat biopsies.RESULTS: Higher potassium intake increased urinary potassium excretion (144.7 ± 28.7 versus 67.5 ± 25.5 mmol/24-h; P < 0.0001) and plasma concentrations of potassium (4.3 ± 0.2 versus 4.0 ± 0.2 mmol/L; P = 0.0002), renin {mean 16 [95% confidence interval (CI) 12-23] versus 11 [5-16] mIU/L; P = 0.0047}, angiotensin II [mean 10.0 (95% CI 6.2-13.0) versus 6.1 (4.0-10.0) pmol/L; P = 0.0025] and aldosterone [mean 440 (95% CI 336-521) versus 237 (173-386) pmol/L; P < 0.0001]. Despite RAAS activation, systolic BP (117.6 ± 5.8 versus 118.2 ± 5.2 mmHg; P = 0.48) and diastolic BP (70.8 ± 6.2 versus 70.8 ± 6.3 mmHg; P = 0.97) were unchanged. In the wire myograph experiments, higher potassium intake did not affect endothelial function as assessed by acetylcholine [logarithmically transformed half maximal effective concentration (pEC50): 7.66 ± 0.95 versus 7.59 ± 0.85; P = 0.86] and substance P (pEC50: 8.42 ± 0.77 versus 8.41 ± 0.89; P = 0.97) or vascular smooth muscle cell reactivity as assessed by angiotensin II (pEC50: 9.01 ± 0.86 versus 9.02 ± 0.59; P = 0.93) and sodium nitroprusside (pEC50: 7.85 ± 1.07 versus 8.25 ± 1.32; P = 0.25) but attenuated the vasodilatory response of retigabine (pEC50: 7.47 ± 1.16 versus 8.14 ± 0.90; P = 0.0084), an activator of Kv7 channels.CONCLUSIONS: Four weeks of increased potassium intake activates the RAAS in normotensive men without changing BP and this is not explained by improved vasodilatory responses ex vivo.

AB - BACKGROUND: Increased potassium intake lowers blood pressure (BP) in hypertensive patients. The underlying mechanism is not fully understood but must be complex because increased potassium intake elevates circulating concentrations of the BP-raising hormone aldosterone.METHODS: In a randomized placebo-controlled crossover study in 25 normotensive men, we investigated the effect of 4 weeks of potassium supplement (90 mmol/day) compared with 4 weeks of placebo on the renin-angiotensin-aldosterone system (RAAS), urine composition and 24-h ambulatory BP. Vascular function was also assessed through wire myograph experiments on subcutaneous resistance arteries from gluteal fat biopsies.RESULTS: Higher potassium intake increased urinary potassium excretion (144.7 ± 28.7 versus 67.5 ± 25.5 mmol/24-h; P < 0.0001) and plasma concentrations of potassium (4.3 ± 0.2 versus 4.0 ± 0.2 mmol/L; P = 0.0002), renin {mean 16 [95% confidence interval (CI) 12-23] versus 11 [5-16] mIU/L; P = 0.0047}, angiotensin II [mean 10.0 (95% CI 6.2-13.0) versus 6.1 (4.0-10.0) pmol/L; P = 0.0025] and aldosterone [mean 440 (95% CI 336-521) versus 237 (173-386) pmol/L; P < 0.0001]. Despite RAAS activation, systolic BP (117.6 ± 5.8 versus 118.2 ± 5.2 mmHg; P = 0.48) and diastolic BP (70.8 ± 6.2 versus 70.8 ± 6.3 mmHg; P = 0.97) were unchanged. In the wire myograph experiments, higher potassium intake did not affect endothelial function as assessed by acetylcholine [logarithmically transformed half maximal effective concentration (pEC50): 7.66 ± 0.95 versus 7.59 ± 0.85; P = 0.86] and substance P (pEC50: 8.42 ± 0.77 versus 8.41 ± 0.89; P = 0.97) or vascular smooth muscle cell reactivity as assessed by angiotensin II (pEC50: 9.01 ± 0.86 versus 9.02 ± 0.59; P = 0.93) and sodium nitroprusside (pEC50: 7.85 ± 1.07 versus 8.25 ± 1.32; P = 0.25) but attenuated the vasodilatory response of retigabine (pEC50: 7.47 ± 1.16 versus 8.14 ± 0.90; P = 0.0084), an activator of Kv7 channels.CONCLUSIONS: Four weeks of increased potassium intake activates the RAAS in normotensive men without changing BP and this is not explained by improved vasodilatory responses ex vivo.

U2 - 10.1093/ndt/gfaa114

DO - 10.1093/ndt/gfaa114

M3 - Journal article

C2 - 32596729

VL - 36

SP - 1282

EP - 1291

JO - Nephrology, Dialysis, Transplantation

JF - Nephrology, Dialysis, Transplantation

SN - 0931-0509

IS - 7

ER -

ID: 244010179